|
Basic Characteristics of Mutations
|
|
Mutation Site
|
D484Y |
|
Mutation Site Sentence
|
We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RdRp |
|
Standardized Encoding Gene
|
ORF1b
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
NC_045512
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
France |
|
Literature Information
|
|
PMID
|
32986807
|
|
Title
|
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019
|
|
Author
|
Martinot M,Jary A,Fafi-Kremer S,Leducq V,Delagreverie H,Garnier M,Pacanowski J,Mekinian A,Pirenne F,Tiberghien P,Calvez V,Humbrecht C,Marcelin AG,Lacombe K
|
|
Journal
|
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
|
|
Journal Info
|
2021 Oct 5;73(7):e1762-e1765
|
|
Abstract
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus for which remdesivir is the only antiviral available. We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia. A cure was achieved after supplementation with convalescent plasma.
|
|
Sequence Data
|
-
|